Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Reverb Therapeutics
Canada
- Vancouver, British columbia
- 21/02/2025
- Seed
- $21,000,000
We develop bispecific antibodies that exploit the potential of the natural immune system. Our Amplify•R platform amplifies and redirects endogenous cytokine signaling instead of recombinant cytokines. We avoid issues such as systemic toxicity, immunogenicity and manufacturing concerns.
- Industry Biotechnology Research
- Website https://www.reverbtx.com/
- LinkedIn https://www.linkedin.com/company/reverbtx/
Related People
David de GraafCo Founder
United States -
Greater Boston
I have the immodest goal of believing I can change the underpinnings of research and development of pharmaceuticals in order to provide integrative, personalized patient care in all therapeutic areas. I think that leadership should provide vision and direction, but I also believe that everyone needs to contribute to filling in that vision in a collaborative and constructive environment. I believe that unique skills are undervalued in large organizations and can shine in smaller ones.
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)